Opinion

Video

Long-term Safety of JAK Inhibitors in Atopic Dermatitis

Key Takeaways

  • Long-term upadacitinib data reveal sustained efficacy and safety, offering insights beyond short-term studies for atopic dermatitis management.
  • Comparisons with other JAK inhibitors highlight differences in long-term outcomes, influencing clinical decision-making.
SHOW MORE

Following a review of findings from the LEVEL UP study, an expert on atopic dermatitis shares what we’ve learned from long-term data on upadacitinib and JAKi.

Video content above is prompted by the following:

  • Are there any learnings from long-term upadacitinib data that were not seen in short-term data?
  • What about short vs long-term data with other JAKi?
  • How do they impact your use of JAKi for atopic dermatitis?
Related Videos
3 experts are featured in this series.
3 experts are featured in this series.
Safety Profile, Accessibility of Tapinarof Cream for Atopic Dermatitis, with Adelaide Hebert, MD
Impact of Tapinarof Cream Approval for Atopic Dermatitis, with Adelaide Hebert, MD
© 2025 MJH Life Sciences

All rights reserved.